A Trial to Assess TEV-56286 at Different Doses in Healthy Participants

The purpose of the trial is to evaluate the pharmacokinetics, safety, and tolerability of TEV-56286 at different doses. The main objective is to describe how TEV-56286 is absorbed, distributed, and removed from the body (the pharmacokinetics) following administration of TEV-56286 in single doses of increasing amounts and multiple doses in healthy participants. A secondary objective is to assess the safety of TEV-56286 and how well it is tolerated. The estimated duration for participants in Part 1 with Single Ascending Dose is approximately 58 days; including up to 45 days of screening, a 4-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit. The estimated duration for participants in Part 2 with Multiple Dose is approximately 64 days; including 45 days of screening, a 10-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit.

NCT Number	NCT07674940
Lead Sponsor	Teva Branded Pharmaceutical Products R&D LLC
Conditions	Healthy Volunteers
Enrollment	60 participants
Start Date	2026-06-26
Primary Completion	2027-01-15 (estimated)
Study Completion	2027-01-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-06